Producer

Haoshu International (Hao Shu Biotech)

HQ CN · Guangxiwebsite ↗

Chinese botanical extraction and pharmaceutical API company headquartered in Guangxi province — the heart of Camptotheca acuminata cultivation territory. Haoshu is among the largest producers of camptothecin and its hydroxylated derivative 10-hydroxycamptothecin (10-OHCPT) extracted from Camptotheca acuminata bark, wood, and leaves, and is a significant irinotecan API manufacturer supplying both domestic Chinese generic pharmaceutical companies and international API buyers. Guangxi's subtropical climate and rich red-clay soils support large Camptotheca acuminata plantations; Haoshu's vertical integration from plantation to API distinguishes it from pure chemical API manufacturers. The company also produces other phytochemical APIs from Chinese medicinal plant sources.

1

Inputs supplied

1

Goods downstream

1

Facilities

0

Stories

What they make

1 input Haoshu International (Hao Shu Biotech) supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where it shows up

Goods downstream

Essential goods that depend on something Haoshu International (Hao Shu Biotech) makes, pick one to see the full supply chain.

What else they do

Business segments

The company's full revenue map, where this supply-chain role fits within their broader business.

  • Camptothecin API (Botanical)

    60%
  • CPT Derivatives & Precursors

    30%
  • Botanical Cultivation & Extraction

    10%

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

  • Did you know2014

    Camptotheca acuminata, the source of camptothecin API for oncology drugs, is also a widely planted ornamental and shade tree in southern China (nicknamed "happy tree" in Chinese — xi shu). Chinese municipal governments plant Camptotheca as boulevard trees, campus trees, and park plantings. The pharmaceutical API supply chain (commercial Camptotheca plantations in Guangxi for camptothecin extraction) and urban forestry use the same tree species. During periods of high camptothecin demand, pharmaceutical buyers have occasionally purchased Camptotheca from municipal park plantings, connecting the global cancer drug supply chain to the management of urban green infrastructure in southern Chinese cities.

    PMC / NLM
  • Origin2023

    Haoshu International is located in Guangxi Province — the primary cultivation region for Camptotheca acuminata (xi shu, "happy tree"), a tree native to southern China. Camptothecin was first identified as an anti-cancer compound by Monroe Wall and Mansukh Wani at the Research Triangle Institute in 1966, using plant material collected by the US National Cancer Institute's natural products screening program — including specimens collected in China. The discovery created Chinese botanical extraction companies to process the tree's bark and wood for the semi-synthetic precursors to irinotecan (CPT-11) and topotecan, two important colon and ovarian cancer drugs. Chinese companies like Haoshu became critical upstream nodes in global oncology supply chains based on their geographic access to Camptotheca cultivation.

    Haoshu International